\
&
Contact us
\
&
Contact us
Published on | 5 months ago
Programmes Enhancing EU R&IThis monitoring report presents an overview of gender equality in EU R&I programmes, particularly in Horizon Europe. It focuses both on main indicators of equality within the programme – such as gender balance of research teams, leading positions, expert evaluations and expert groups – and then on how concretely the programme addresses the issue of gender equality in R&I, such as through requesting adoption of Gender Equality Plans, promoting gender mainstreaming in research, and addressing gender gaps in innovative entrepreneurship. (from the back cover)
1. Introduction (p.3)
2. Key indicators: women participation across the Framework Programmes (p. 8)
3. Project coordinators (p. 9)
4. Project researchers (p. 10)
5. Empowering women innovators (p. 14)
6. Gender equality plans (GEPs) as eligibility criterion (p. 15)
7. Integration of the gender dimension in R&I activities in Horizon Europe (p. 18)
8. Gender equality in European Partnerships (p. 22)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
